45 results about "Gamma-glutamyltransferase" patented technology

The bacillus subtilis NX-2, or CGMCC NO.0833 is one bacillus spawn obtained through screening and is used for the production of gamma-polyglutamic acid and its salt as well as glutathione and its precursor. In optimized condition, gamma-polyglutamic acid may be accumulated to 30-50 g / L and produced in the production efficinecy of 0.8-2.5 g / L. When bacillus subtilis NX-2 is used in fermenting to produce gamma-glutamyl transpeptidase in optimized condition, the fermented liquid may reach enzyme activity of 1-5 U / ml; and the fermented liquid or separation obtained enzyme or the immobilized enzyme is used in the production of glutathione and its precursor with substrate dipeptide or dipeptide precursor converting rate of 30-80% being reached.

The invention relates to a natural theanine preparing method, which belongs to the technical field of the biologic engineering. Bacillus subtilis SK11.004 strain obtained through separating and selecting the Chinese traditional fermentation food is theanine producing strain of gamma-glutamyltransferase with the collection number CCTCC NO of M 208083; Gamma-glutamyl transpeptidase is acted on glutamine and ethylamine, and under the condition of pH 10, the theanine can be efficiently produced. The enzyme preparing method for theanine of the invention has the advantages that the reaction time is short, the preparation of the enzyme activity source is simple, the production of the theanine is ensured to be simple, and the product is safe and reliable. The preparing method is suitable for performing large-scale industrialized production.

The present invention enhances the effects of antitumor agents and increases the sensitivity of therapy-resistant tumor cells to antitumor agents such as chemotherapeutic agents and radiation. The present invention is thus directed to compositions and methods for inhibiting and killing neoplastic cancer cells, for example for the treatment, inhibition or prevention of tumors or malignant growths or other neoplasias in mammals. The GGT inhibitor compounds used in the methods of the present invention comprise a class of benzylthiadiazol benzenesulfoniamides represented by the general structure Formula (I) (FIG. 1), or a pharmaceutically acceptable salt thereof, wherein any one or more of R1-R10 may be H, Cl, F, Br, I, OH, an alkoxy, or NO2. Other R groups include carrier groups linked by C,N, or O. The present invention also provides a method for the prophylaxis or treatment of a reversible airways obstruction in a mammal, such as a human, comprising administration of a therapeutically effective amount of a GGT inhibitor described herein for the prophylaxis or treatment of a disease associated with reverse airways obstruction such as asthma, chronic obstructive pulmonary disease (COPD), allergic reaction, respiratory tract infection or upper respiratory tract disease. Other diseases or conditions which may be treated include, for example, degenerative diseases, renal diseases, liver diseases, and inner ear conditions or diseases.

The invention discloses a preparation method of sulfur-allyl-L-cysteine. The preparation method comprises the following steps of dissolving gamma-glutamoyl-sulfur-allyl-L-cysteine in a buffer solution, and adding gamma-glutamyl transpeptidase as a catalyst to the buffer solution for reaction so as to obtain a reaction liquid containing the sulfur-allyl-L-cysteine; sending the reaction liquid to a chromatographic column for adsorption separation, washing with de-ionized water and eluting by using a 0.3 mol / L-1.2 mol / L ammonia solution, and collecting an eluant containing the sulfur-allyl-L-cysteine; adding a solvent after the eluant is subjected to evaporation and concentration, stewing at a room temperature and separating out crystals; washing the crystals with ethanol, and recrystallizing by using an ethanol solution with the volume fraction of 60% after the crystals are dried so as to obtain the crystals containing the sulfur-allyl-L-cysteine. The preparation method of the sulfur-allyl-L-cysteine has the advantages that preparing the sulfur-allyl-L-cysteine is prepared in a high yield and the problem that the sulfur-allyl-L-cysteine is oxidized into alliin by oxidase in garlic cells is avoided.

The present invention discloses chemical enzymatic process of synthesizing glutathion. The chemical enzymatic process includes the following steps: A. synthesizing substrate chemically; B. preparing gamma-glutamyl transpeptidase; and C. adding gamma-glutamyl transpeptidase into the substrate solution to produce transpeptidase reaction preparing glutathion. The said substrate is S-benzyl-cysteinyl glycine and L-glutamine. The process is simple, low in cost and high in glutathion converting rate, and may be used in industrial production.

The invention discloses to further optimization of a process for generating L-theanine from L-glutamine and ethylamine catalyzed by gamma-glutamyl transpeptidase secreted from recombinant pMA5-ggt / Bacillus. subtilis by using a method that double substrates are added in different batches, and belongs to the field of fermentation engineering and enzyme engineering. The process comprises the following steps: culturing the strain of bacillus subtilis which is established in previous operation and is used for secreting gamma-glutamyl transpeptidase in a fermentation tank; concentrating supernate crude enzyme liquid for conversion of theanine; on the basis, adding the substrates in different batches so as to further regulate and control the conversion process, that is, in a reaction system with 60U / mL of the enzyme liquid, adding substrates glutamine and ethylamine into the system every other two hours, wherein the addition amount of glutamine is fixed to be 20 mM, the ratio of a donor to a receptor is controlled to be 1:12, the pH value is adjusted to be 10, 164.2 mM of theanine can be obtained after 18 hours, and the conversion rate of glutamine can be up to 91.2%. The method has the advantages that the operation is simple, the cost is low, the yield of theanine is high, the substrate conversion rate is high, and the like, and is beneficial for industrial large-scale production.

The bacillus subtilis NX-2, or CGMCC NO.0833 is one bacillus spawn obtained through screening and is used for the production of gamma-polyglutamic acid and its salt as well as glutathione and its precursor. In optimized condition, gamma-polyglutamic acid may be accumulated to 30-50 g / L and produced in the production efficinecy of 0.8-2.5 g / L. When bacillus subtilis NX-2 is used in fermenting to produce gamma-glutamyl transpeptidase in optimized condition, the fermented liquid may reach enzyme activity of 1-5 U / ml; and the fermented liquid or separation obtained enzyme or the immobilized enzyme is used in the production of glutathione and its precursor with substrate dipeptide or dipeptide precursor converting rate of 30-80% being reached.

Compositions and methods for inhibiting human gamma-glutamyl transpeptidase (GGT) in vivo or in vitro and for inhibiting and killing neoplastic cancer cells, for example for the treatment, inhibition or prevention of tumors or malignant growths or other neoplasias in mammals, or sensitizing tumor to other therapies including radiation therapy. The GGT inhibitor compounds comprise a class of benzylthiadiazol benzenesulfoniamides. The compounds may also be used to treat a reversible airways obstruction in a mammal or a disease associated with reverse airways obstruction such as asthma, chronic obstructive pulmonary disease (COPD), allergic reaction, respiratory tract infection or upper respiratory tract disease. Other diseases or conditions which may be treated include, for example, degenerative diseases, renal diseases, liver diseases, cardiovascular disease and inner ear conditions or diseases.

The invention discloses application of monomeric compounds of fruits of Chinese magnoliavine (Schisandra chinensis(Turcz.) baill. and Schisandra sphenanthera Rehd.et Wils) to preparation of medicine for preventing and treating cholestasis liver diseases. The monomeric compounds of fruits of Chinese magnoliavine refer to Schisandrin B, Schisandrin C, Schisandrol A, Schisantherrin A and Schisantherrin B. The result of the study shows that all of the five kinds of monomeric compounds can obviously reduce the content of total bile acids and direct bilirubin in blood serum in the cholestasis liverdisease state, can relieve the cholestasis symptoms, can reduce the activity of alkaline phosphatase, gamma-glutamyltransferase, aspartate transaminase and / or alanine aminotransferase in the liver, and can effectively improve the liver tissue necrosis degree. The invention discovers the condition for the first time that the five kinds of monomeric compounds of fruits of Chinese magnoliavine can beused for effectively preventing and treating the cholestasis liver diseases induced by liithocholic acid. The discovery provides the powerful technical theoretical basis for the new medicine researchand development for the cholestasis liver diseases and the clinic application of the monomeric compounds of fruits of Chinese magnoliavine; and wide application prospects are realized in the field ofcholestasis prevention and treatment.

The invention discloses a method for preparing a theanine by an interspecific coupling ATP regenerative technology comprising the following steps: preparing gamma-glutamyltransferase immobilized cells by using bacillus licheniformis, preparing 1,6-diphosphate conversion culture solution by using bacillus stearothermophilus; preparing the theanine conversion solution by mixing the gamma-glutamyltransferase immobilized cells, 1,6-diphosphate conversion culture solution and substrates which are glutamine (glutamic acid) and ethylamine; obtaining the theanine by extracting and refining the theanine conversion liquid. The technical scheme provided by the invention is a fine new technical scheme for theanine preparation by coupling the ATP regenerative technology and an enzyme conversion technology, a technology capable of promoting the ATP consumed enzyme reaction smooth, also a technology suitable for the theanine production by the microorganism conversion method and has a wide application prospect in the food, medical treatment and the enzyme engineering field.

Compositions and methods for inhibiting human gamma-glutamyl transpeptidase (GGT) in vivo or in vitro and for inhibiting and killing neoplastic cancer cells, for example for the treatment, inhibition or prevention of tumors or malignant growths or other neoplasias in mammals, or sensitizing tumor to other therapies including radiation therapy. The GGT inhibitor compounds comprise a class of benzylthiadiazol benzenesulfoniamides. The compounds may also be used to treat a reversible airways obstruction in a mammal or a disease associated with reverse airways obstruction such as asthma, chronic obstructive pulmonary disease (COPD), allergic reaction, respiratory tract infection or upper respiratory tract disease. Other diseases or conditions which may be treated include, for example, degenerative diseases, renal diseases, liver diseases, cardiovascular disease and inner ear conditions or diseases.